These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27497026)

  • 1. Revisiting IL-6 antagonism in multiple myeloma.
    Matthes T; Manfroi B; Huard B
    Crit Rev Oncol Hematol; 2016 Sep; 105():1-4. PubMed ID: 27497026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow.
    Matthes T; Manfroi B; Zeller A; Dunand-Sauthier I; Bogen B; Huard B
    Leukemia; 2015 Sep; 29(9):1882-90. PubMed ID: 26159051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.
    Rosean TR; Tompkins VS; Tricot G; Holman CJ; Olivier AK; Zhan F; Janz S
    Immunol Res; 2014 Aug; 59(1-3):188-202. PubMed ID: 24845460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma.
    Portier M; Rajzbaum G; Zhang XG; Attal M; Rusalen C; Wijdenes J; Mannoni P; Maraninchi D; Piechaczyk M; Bataille R
    Eur J Immunol; 1991 Jul; 21(7):1759-62. PubMed ID: 2060582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line.
    Westendorf JJ; Ahmann GJ; Armitage RJ; Spriggs MK; Lust JA; Greipp PR; Katzmann JA; Jelinek DF
    J Immunol; 1994 Jan; 152(1):117-28. PubMed ID: 7504707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulated production of IL-6, but not IL-10, by interferon-alpha induces SOCS3 expression and attenuates STAT1 phosphorylation in myeloma cells.
    Usui E; Nishii K; Katayama N; Lorenzo V F; Chen F; Monma F; Otsuki T; Shiku H
    Hematol J; 2004; 5(6):505-12. PubMed ID: 15570293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TLR5 activation by flagellin induces doxorubicin resistance via interleukin-6 (IL-6) expression in two multiple myeloma cells.
    Cho HY; Lee SW
    Cell Immunol; 2014; 289(1-2):27-35. PubMed ID: 24709011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel insights into the role of interleukin-27 and interleukin-23 in human malignant and normal plasma cells.
    Giuliani N; Airoldi I
    Clin Cancer Res; 2011 Nov; 17(22):6963-70. PubMed ID: 21880791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells?
    Kovacs E
    Leuk Res; 2010 Jul; 34(7):912-6. PubMed ID: 19762082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors.
    Jourdan M; Mahtouk K; Veyrune JL; Couderc G; Fiol G; Redal N; Duperray C; De Vos J; Klein B
    Eur Cytokine Netw; 2005; 16(1):57-64. PubMed ID: 15809207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
    Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R
    Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of interleukin 16 in multiple myeloma.
    Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
    J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells.
    Efferth T; Fabry U; Osieka R
    Anticancer Res; 2002; 22(1A):231-4. PubMed ID: 12017294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro Ig-synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors.
    Sonneveld P; Schoester M; de Leeuw K
    Br J Haematol; 1991 Dec; 79(4):589-94. PubMed ID: 1772780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.
    Colombo M; Galletti S; Bulfamante G; Falleni M; Tosi D; Todoerti K; Lazzari E; Crews LA; Jamieson CH; Ravaioli S; Baccianti F; Garavelli S; Platonova N; Neri A; Chiaramonte R
    Oncotarget; 2016 Aug; 7(35):56013-56029. PubMed ID: 27463014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
    Westendorf JJ; Jelinek DF
    J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Myeloma. Advances in disease biology: therapeutic implications.
    Anderson KC
    Semin Hematol; 2001 Apr; 38(2 Suppl 3):6-10. PubMed ID: 11309702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.